Navigation Links
Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Date:1/19/2009

anies in Wallonia at the cutting-edge of technology by providing financing solutions in a difficult financial environment."

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle. An international clinical trial of C-Cure sponsored by Cardio3 BioSciences is expected to begin in early 2009.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

About C-Cure(R)

C-Cure is a second generation cell therapy for the treatment of heart failure that involves taking a patient's own stem cells from bone marrow and through a proprietary culturing technology generating differentiated 'cardiopoeitic' cells which can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

C-Cure draws on the unrivalled understanding of the fundamental science of heart cell development within Cardio3 BioSciences and on technology developed at Mayo Clinic, one o
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop focused ... Zealand Forensic Science Society,s 22 nd International ... Adelaide, Australia .  Forensic Scientists will be ... hyperspectral imaging can bring to examination procedures. ... of Product Development at ChemImage, will host a ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... August 30, 2014 “In 2013, a vehicle ... Jones Firm says in a recently released article on ... was injured in an auto accident every 12 minutes, and ... they continue. “Based on the 2013 statistics, between now and ... collision.” , The threat of an auto accident is real ...
(Date:8/30/2014)... MA (PRWEB) August 30, 2014 Barton ... nurse practitioner locum tenens company , announces a ... September 1, 2014. Barton Associates is headquartered in Peabody, ... CT; Keene, NH; and Jupiter, FL. , ... to the increasing demand for healthcare providers. The United ...
(Date:8/30/2014)... 2014: The first multidisciplinary recommendations on the management ... (ACS) are published today in EP Europace ... by the European Heart Rhythm Association (EHRA), the ... Association of Percutaneous Cardiovascular Interventions (EAPCI), all of ... chairperson of the task force, said: "Sudden cardiac ...
(Date:8/30/2014)... Saturday 30 August 2014: The therapeutic benefit ... emphasised in the 2014 ESC/EACTS revascularisation guidelines presented ... Professor Stephan Windecker (Switzerland) of the European Society ... of the European Association for Cardio-Thoracic Surgery (EACTS). ... European Heart Journal (1), on the ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 AGH Healthy ... the Doctors in Delaware at Atlantic General ... free health-related services. In addition to no-cost blood pressure ... offers first aid care at local sports tournaments. ... other medical staff provide free disease management and falls ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... The pharmaceutical industry is a "market for lemons," a ... buyer about the product and can profit from selling products ... believe, according to an analysis that will be presented at ... "Sometimes drug companies hide or downplay information about serious side ...
... study shows the impact of alcohol intoxication on reasoning ... feel they have recovered enough to drive after drinking. ... president of research for Lifespan, is the first to ... rising and declining blood alcohol concentrations, at matched blood ...
... , TUESDAY, Aug. 17 (HealthDay News) -- Nearly 40 percent ... episodes of manic behavior, a new study suggests. Researchers ... that these patients have what,s called "subthreshold hypomania" -- meaning ... days, and is therefore below the threshold for bipolar disorder. ...
... Community Living Assistance Services and Supports (CLASS) Act a ... Care Act has the potential to transform long-term care ... insurance-based system, according to the latest issue of ... With funding from The SCAN Foundation , this ...
... for airway repair in the lung but that persist in ... poor prognosis in patients who develop cancer, even those with ... have found. These adult stem cells are found in ... areas, suggesting that these cells may mutate and become cancer ...
... an Aging America" will be the focus of the 24th ... Aging from 8 a.m. to 3:30 p.m. Wednesday, Sept. 8 ... The conference, sponsored by The University of Texas Health ... Aging, will include panel discussions, a keynote address by Robert ...
Cached Medicine News:Health News:Pharmaceuticals: A market for producing 'lemons' and serious harm 2Health News:Pharmaceuticals: A market for producing 'lemons' and serious harm 3Health News:Why drunk drivers may get behind the wheel 2Health News:Why drunk drivers may get behind the wheel 3Health News:Many Depressed People Have Mild, Brief Episodes of Mania 2Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor 2
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, starter package accessory ... adapter, specimen mounts 1/2" head, ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
... with a square vice mounting device. ... for mounting specimens and placing in ... blocks are annodized black for easy ... They are shipped three to ...
Medicine Products: